Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Biosecurity Vaccine Tech topic
No spam. Unsubscribe anytime.
Committee hears request to study 'self‑spreading' vaccine technology and risks
Summary
Representative Donna Henderson asked the Senate Human Services Committee to authorize a study of self‑replicating, potentially transmissible RNA vaccine technologies. Supporters urged caution and study; no opposition testimony was heard in committee.
Representative Donna Henderson introduced House Bill 1458 seeking a legislative study on "self‑spreading" or self‑replicating viral and RNA vaccine technologies. Henderson told the committee she and others are concerned about research that, she said, could permit replication or transmission of engineered RNA elements beyond an intended recipient and asked lawmakers to study risks, impacts and possible guardrails.
Henderson described scientific commentary and controversy about a class of self‑replicating mRNA vaccines that amplify antigen production within recipient cells. She cited comments attributed to an academic in Tokyo and warned of a hypothetical “shedding” or transfer risk; she asked the committee to authorize a study rather than an immediate ban so legislators could gather expert evidence before deciding on policy.
Remote witness Charlene Nelson urged the committee to act now to commission study and said she had provided links and documents to the committee record. She compared the issue to prior debates over gain‑of‑function research and said a study would give the legislature options for protective rules before technologies are deployed.
Committee members asked sponsors how a study would be scoped and which experts would be summoned; Henderson said a study would bring in scientific experts, public‑health agencies and private research entities to collect data and make recommendations. Senators also expressed skepticism about legislatures solving highly technical virology questions but acknowledged the possible value of a targeted, expert‑led study.
No opposition testimony was recorded in the transcript and the committee did not record a vote in the hearing portion available in the transcript. The committee closed the public hearing after taking remote testimony.
